Tirzepatide blunts nicotine reward and accumbal dopamine in male mice
The dual GIP/GLP-1 agonist also suppressed reinstatement of nicotine place preference and prevented expression of locomotor sensitisation, per British Journal of Pharmacology.
PR
By Priya Raman · Science Reporter
Sep 27 20:00 ETSource: British journal of pharmacology
The wire
- 01In male mice, tirzepatide dose-dependently attenuated nicotine-induced locomotor stimulation, reduced conditioned place preference and lowered nicotine-induced dopamine release in the nucleus accumbens.
- 02Adds incretin agonists to the list of candidates being explored for nicotine dependence, where relapse and post-cessation weight gain remain barriers.
- 03Animal study in male mice only, with no human data on smoking cessation; effects on GABA and other transmitters were region-specific and mechanistically unresolved.
From the source
Read at pubmed.ncbi.nlm.nih.govThe dual incretin agonist tirzepatide blunts nicotine-induced behaviours and neurochemistry in male mice
British journal of pharmacology · 2026 Sep 28 · Edvardsson CE, Emous TA, Witley S et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42805610/
